What is the guideline‑directed medical management for a patient with heart failure, including both reduced and preserved ejection fraction?

Guideline-Directed Medical Management for Heart Failure

For heart failure with reduced ejection fraction (HFrEF), initiate quadruple therapy with an ARNI (sacubitril/valsartan), beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor, titrating to target doses within 6-12 weeks; for HFpEF, initiate an SGLT2 inhibitor as the primary disease-modifying therapy. 1, 2

Heart Failure with Reduced Ejection Fraction (HFrEF)

Essential Quadruple Therapy (All Four Classes Required)

The evidence is unequivocal that four drug classes form the foundation of HFrEF management, each providing at least 20% mortality reduction 1:

1. Renin-Angiotensin System Inhibition:

• First-line: ARNI (sacubitril/valsartan) - provides superior mortality benefit over ACE inhibitors alone 1
• Alternative: ACE inhibitors or ARBs if ARNI not tolerated (though these provide only modest 5-16% mortality reduction and do not reduce sudden death) 1

2. Beta-Blockers (Evidence-Based Agents Only):

• Carvedilol, metoprolol succinate, or bisoprolol - these specific agents reduce mortality by ≥20% and prevent sudden death 1
• Do NOT substitute with other beta-blockers (e.g., metoprolol tartrate) as they lack mortality data 1

3. Mineralocorticoid Receptor Antagonists:

• Spironolactone or eplerenone - reduce mortality ≥20% and prevent sudden death 1, 3
• Essential even in stable patients due to sudden death prevention 1

4. SGLT2 Inhibitors:

• Dapagliflozin or empagliflozin - reduce cardiovascular death and HF hospitalizations 2, 4
• Initiate early regardless of diabetes status 2

Critical Implementation Strategy: Forced Titration

The landmark trials used "forced-titration" protocols that are rarely followed in practice but are essential for mortality benefit 1:

• Start at low doses
• Uptitrate at specific intervals (typically every 1-2 weeks) to target doses
• Target doses are the SAME for all patients, not individualized
• Asymptomatic vital sign or lab changes do NOT justify stopping uptitration
• Only persistent, clinically significant adverse events warrant dose reduction
• If therapy is interrupted, aggressively reinitiate and re-escalate 1

Common Pitfall: Most patients in real-world practice receive only starting doses indefinitely, which has unproven mortality benefit 1, 5. The evidence supporting guideline recommendations is based on achieving target doses through forced titration.

Timeline for Initiation

All four drug classes should be initiated within 6-12 weeks of diagnosis 2, 4. The 2022 AHA/ACC guidelines emphasize early, rapid initiation rather than sequential addition 2.

Secondary Therapies (For Persistent Symptoms)

After optimizing quadruple therapy:

• Digoxin: For symptom control in sinus rhythm or rate control in atrial fibrillation 3
• Hydralazine/isosorbide dinitrate: Particularly in Black patients or ACE inhibitor intolerance 1
• Ivabradine: If heart rate >70 bpm on maximally tolerated beta-blocker 4
• Vericiguat: For worsening HF despite GDMT 4

Diuretics

Loop diuretics for congestion management - essential for symptom relief but do not reduce mortality 6, 3:

• Titrate to euvolemia
• If inadequate response: increase dose, give twice daily, or add thiazide 3
• Avoid thiazides if GFR <30 mL/min unless combined with loop diuretics 3

Managing Adverse Effects

Do not prematurely discontinue therapy for common side effects 1:

• Hypotension: If asymptomatic, continue uptitration; adjust timing of doses
• Hyperkalemia: Reduce/stop potassium supplements and potassium-sparing diuretics before stopping MRA
• Worsening renal function: Small increases in creatinine (up to 30%) are acceptable; avoid NSAIDs 3
• Cough with ACE inhibitors: Switch to ARB or ARNI

Heart Failure with Preserved Ejection Fraction (HFpEF)

The management paradigm for HFpEF has fundamentally changed with breakthrough SGLT2 inhibitor data 7.

Primary Disease-Modifying Therapy

SGLT2 Inhibitors (First-Line):

• Empagliflozin or dapagliflozin - reduce composite of cardiovascular death and HF hospitalizations 7
• This represents the ONLY proven disease-modifying therapy for HFpEF 7
• Initiate regardless of diabetes status 2

Supportive Management

Diuretics for congestion - symptom management only 7

Aggressive comorbidity management 7:

• Hypertension control
• Diabetes management
• Obesity treatment (consider GLP-1 agonists)
• Atrial fibrillation rate/rhythm control
• Coronary artery disease management

Limited Evidence Therapies

• ARNIs (sacubitril/valsartan): May reduce HF hospitalizations in select patients but mortality benefit unclear 7
• MRAs (spironolactone, finerenone): Emerging evidence, particularly finerenone, but not yet standard 8, 9

Critical Note: Unlike HFrEF, there is NO established quadruple therapy for HFpEF. The focus remains on SGLT2 inhibitors plus aggressive comorbidity management 7.

Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)

Treat similarly to HFrEF with the same quadruple therapy approach 2, 10:

• ARNI or ACE inhibitor/ARB
• Beta-blocker
• MRA
• SGLT2 inhibitor

The 2022 guidelines eliminated the term "mid-range" and now recommend HFrEF-type therapies for this population 2, 10.

Monitoring Parameters

Check at 1-2 weeks after each dose increase, then at 3 months, then every 6 months 3:

• Blood pressure
• Heart rate
• Renal function (creatinine, eGFR)
• Electrolytes (potassium, sodium)
• Volume status

Real-World Implementation Gap

The evidence reveals a massive treatment gap 5: Only 1-2% of HFrEF patients receive quadruple therapy despite guideline recommendations. Post-hospitalization, initiation is delayed (mean 88 days for SGLT2i) and discontinuation rates are high (51-62% at 12 months) 5. This represents a critical quality-of-care issue requiring systematic intervention.